Sartorius Stedim Biotech SA
DIM
Company Profile
Business description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact
Otto-Brenner-Strasse 20
Goettingen37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
10,456
Stocks News & Analysis
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks
This US AI champion’s stock is too cheap to ignore
Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks
Why SpaceX is coming to your Super Fund
Most Australians will end up owning SpaceX — whether they like it or not.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,045.50 | 27.70 | -0.31% |
| CAC 40 | 8,467.98 | 37.19 | 0.44% |
| DAX 40 | 25,026.80 | 92.13 | 0.37% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,399.70 | 108.91 | -1.04% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,608.72 | 555.23 | 0.78% |
| NZX 50 Index | 13,416.34 | 53.03 | 0.40% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,827.00 | 29.60 | -0.33% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |